WHO ICTRP trial
Protocol of study on the therapeutic tolerability of Artequick/Femse/Togo
ChiCTR-POC-16009019 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-POC-16009019 |
|---|---|
| Public title | Protocol of study on the therapeutic tolerability of Artequick/Femse/Togo |
| Scientific title | Protocol of study on the therapeutic tolerability of Artequick/Femse/Togo |
| Primary sponsor | Guangzhou University of Chinese Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Prevention |
| Phase | Other |
| Countries | Togo |
| Conditions | Malaria |
| Interventions | Mass Drug Treatement with Artemisinin-Piperaquine:Mass Drug Treatement with Artemisinin-Piperaquine, and three (3) mass drug administrations with Artequick during 3 months, 1 MDA per month |
| Registration date | Aug 13, 2016 |
| Target size | Mass Drug Treatement with Artemisinin-Piperaquine:125611 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: